Real‐world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus

Lixin Guo is on the advisory boards/consultant for Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Dreisamtech, Dongbao, Eli Lilly, Gan & Lee, Hansoh, Hengrui, Hua Medicine, Huadong Medicine, Innovent Bio, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Synapsor, Takeda, Zense and 3SBIO. Lixin Guo received funding from National Natural Science Foundation of China, Beijing Natural Science Foundation, and was also the recipient of research grants from Abbott, AstraZeneca, Bayer, Dreisamtech, Eli Lilly, Hansoh, Hengrui, Hua Medicine, Huadong Medicine, Innovent Bio, Meitekanger Tech, Novo Nordisk, Salubris Bio, Sanofi, Synapsor and Zense. Guangyu Wu is an employee of Eli Lilly and Company. Jiawei Xu, Yihua Wang and Si Si are employees of Eli Lily and hold equity in Eli Lilly and Company. Yue Xi, Li Li, Kunquan Guo and Jun Wu have no conflicts of interest to disclose. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15590. The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request. Data S1. Supporting Information. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.